ReviewMedComm2026
Chronic Pain: Epidemiology, Pathophysiology, and Clinical Management.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain represents a pervasive global health crisis and a leading cause of disability, yet its management remains challenged by the intricate heterogeneity of its underlying mechanisms. Transcending traditional symptom-based paradigms, chronic pain is now recognized as a distinct disease entity driven by multidimensional maladaptive plasticity. In this review, we synthesize the current landscape of chronic pain, bridging macrolevel epidemiological burdens with microlevel pathophysiological insights. We dissect the complex biological networks driving pain chronification, ranging from peripheral sensitization and ion channel dysfunction to central synaptic reorganization, spinal disinhibition, and maladaptive neuro-immune crosstalk involving glial activation and autoantibody-mediated mechanisms. Notably, we highlight emerging frontiers, including sexual dimorphism in immune signaling, metabolic reprogramming, and epigenetic memory. Furthermore, we critically evaluate the evolution of clinical management strategies, integrating pharmacological innovations, advanced neuromodulation, and digital therapeutics. Finally, we address the persistent translational chasm between basic discovery and clinical efficacy, advocating for a paradigm shift from "one-size-fits-all" approaches toward mechanism-based precision medicine-underpinned by robust biomarkers and deep phenotyping-to revolutionize therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.